The intraductal approach to breast cancer biomarker discovery

Journal of Clinical Oncology

Volumn 24, Issue 7, 2006, Pages 1209-1216

  Dua, R Sascha ^a   Isacke, Clare M ^a   Gui, Gerald P H ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; BIOLOGICAL MARKER; CARCINOEMBRYONIC ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KALLIKREIN; PROSTATE SPECIFIC ANTIGEN; UROKINASE RECEPTOR; ANGIOGENIC FACTOR; CELL SURFACE RECEPTOR; PLASMINOGEN ACTIVATOR, UROKINASE RECEPTORS; TUMOR MARKER; TUMOR PROTEIN;

ANGIOGENESIS; ASPIRATION; BREAST CANCER; CANCER DIAGNOSIS; DIAGNOSTIC PROCEDURE; ENDOSCOPY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GENOME; HUMAN; INTRADUCTAL CARCINOMA; MICROENVIRONMENT; PRIORITY JOURNAL; PROTEOMICS; REVIEW; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; BREAST TUMOR; CELL TRANSFORMATION; CHEMISTRY; CHROMOSOMAL INSTABILITY; DNA METHYLATION; ENDOSCOPE; EQUIPMENT DESIGN; FEMALE; GENETICS; HETEROZYGOSITY LOSS; INSTRUMENTATION; LAVAGE; MAMMARY GLAND; MASS SPECTROMETRY; METHODOLOGY; NEEDLE BIOPSY; NIPPLE; PATHOLOGY; SENSITIVITY AND SPECIFICITY;

ANGIOGENESIS INDUCING AGENTS; BIOPSY, FINE-NEEDLE; BREAST NEOPLASMS; CARCINOEMBRYONIC ANTIGEN; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOMAL INSTABILITY; DNA METHYLATION; ENDOSCOPES; ENDOSCOPY; EQUIPMENT DESIGN; FEMALE; HUMANS; IRRIGATION; KALLIKREINS; LOSS OF HETEROZYGOSITY; MAMMARY GLANDS, HUMAN; NEOPLASM PROTEINS; NIPPLES; PROTEOMICS; RECEPTOR, ERBB-2; RECEPTORS, CELL SURFACE; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 33644980249     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.04.1830     Document Type: Review

References (59)

1. Ciatto S, Rosselli Del Turco M, Zappa M: The detectability of breast cancer by screening mammography. Br J Cancer 71:337-339, 1995
2. Esserman L, Cowley H, Eberle C, et al: Improving the accuracy of mammography: Volume and outcome relationships. J Natl Cancer Inst 94:369-375, 2002
3. Destounis SV, DiNitto P, Logan-Young W, et al: Can computer-aided detection with double reading of screening mammograms help decrease the false-negative rate? Initial experience. Radiology 232:578-584, 2004
4. Papanicolaou GN, Holmquist DG, Bader GM, et al: Exfoliative cytology of the human mammary gland and its value in the diagnosis of cancer and other diseases of the breast. Cancer 11:377-409, 1958
5. Sauter ER, Ross E, Daly M, et al: Nipple aspirate fluid: A promising non-invasive method to identify cellular markers of breast cancer risk. Br J Cancer 76:494-501, 1997
6. King EB, Chew KL, Petrakis NL, et al: Nipple aspirate cytology for the study of breast cancer precursors. J Natl Cancer Inst 71:1115-1121, 1983
7. Wrensch MR, Petrakis NL, Gruenke LD, et al: Factors associated with obtaining nipple aspirate fluid: Analysis of 1428 women and literature review. Breast Cancer Res Treat 15:39-51, 1990
8. Lee MM, Wrensch MR, Miike R, et al: The association of dietary fat with ability to obtain breast fluid by nipple aspiration. Cancer Epidemiol Biomarkers Prev 1:277-280, 1992
9. Petrakis NL, Barnes S, King EB, et al: Stimulatory influence of soy protein isolate on breast secretion in pre- and postmenopausal women. Cancer Epidemiol Biomarkers Prev 5:785-794, 1996
10. Sauter ER, Daly M, Linahan K, et al: Prostate-specific antigen levels in nipple aspirate fluid correlate with breast cancer risk. Cancer Epidemiol Biomarkers Prev 5:967-970, 1996
11. Dooley WC, Ljung BM, Veronesi U, et al: Ductal lavage for detection of cellular atypia in women at high risk for breast cancer. J Natl Cancer Inst 93:1624-1632, 2001
12. Tebeoul M: Atlas of ultrasound and ductal echography of the breast. Oxford, United Kingdom, Blackwell Science, 1995
13. Makita M, Sakamoto G, Akiyama F, et al: Duct endoscopy and endoscopic biopsy in the evaluation of nipple discharge. Breast Cancer Res Treat 18:179-187, 1991
14. Okazaki A, Okazaki M, Asaishi K, et al: Fiberoptic ductoscopy of the breast: A new diagnostic procedure for nipple discharge. Jpn J Clin Oncol 21:188-193, 1991
15. Shen KW, Wu J, Lu JS, et al: Fiberoptic ductoscopy for patients with nipple discharge. Cancer 89:1512-1519, 2000
16. Dooley WC: Routine operative breast endoscopy during lumpectomy. Ann Surg Oncol 10:38-42, 2003
17. Sartorius OW, Smith HS, Morris P, et al: Cytologic evaluation of breast fluid in the detection of breast disease. J Natl Cancer Inst 59:1073-1080, 1977
18. King EB, Barrett D, Petrakis NL: Cellular composition of the nipple aspirate specimen of breast fluid: II. Abnormal findings. Am J Clin Pathol 64:739-748, 1975
19. King EB, Barrett D, King MC, et al: Cellular composition of the nipple aspirate specimen of breast fluid: I. The benign cells. Am J Clin Pathol 64:728-738, 1975
20. Wrensch MR, Petrakis NL, King EB, et al: Breast cancer incidence in women with abnormal cytology in nipple aspirates of breast fluid. Am J Epidemiol 135:130-141, 1992
21. Wrensch M, Petrakis NL, King EB, et al: Breast cancer risk associated with abnormal cytology in nipple aspirates of breast fluid and prior history of breast biopsy. Am J Epidemiol 137:829-833, 1993
22. Krishnamurthy S, Sneige N, Thompson PA, et al: Nipple aspirate fluid cytology in breast carcinoma. Cancer 99:97-104, 2003
23. Zhu W, Qin W, Ehya H, et al: Microsatellite changes in nipple aspirate fluid and breast tissue from women with breast carcinoma or its precursors. Clin Cancer Res 9:3029-3033, 2003
24. Evron E, Dooley WC, Umbricht CB, et al: Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR. Lancet 357:1335-1336, 2001
25. Krassenstein R, Sauter E, Dulaimi E, et al: Detection of breast cancer in nipple aspirate fluid by CpG island hypermethylation. Clin Cancer Res 10:28-32, 2004
26. Herman JG, Merlo A, Mao L, et al: Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55:4525-4530, 1995
27. Esteller M, Fraga MF, Guo M, et al: DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet 10:3001-3007, 2001
28. King BL, Tsai SC, Gryga ME, et al: Detection of chromosomal instability in paired breast surgery and ductal lavage specimens by interphase fluorescence in situ hybridization. Clin Cancer Res 9:1509-1516, 2003
29. Petrakis NL: Nipple aspirate fluid in epidemiologic studies of breast disease. Epidemiol Rev 15:188-195, 1993
30. Petrakis NL: Physiologic, biochemical, and cytologic aspects of nipple aspirate fluid. Breast Cancer Res Treat 8:7-19, 1986
31. Zhao Y, Verselis SJ, Klar N, et al: Nipple fluid carcinoembryonic antigen and prostate-specific antigen in cancer-bearing and tumor-free breasts. J Clin Oncol 19:1462-1467, 2001
32. Chatterton RT Jr, Geiger AS, Khan SA, et al: Variation in estradiol, estradiol precursors, and estrogen-related products in nipple aspirate fluid from normal premenopausal women. Cancer Epidemiol Biomarkers Prev 13:928-935, 2004
33. Chatterton RT Jr, Geiger AS, Mateo ET, et al: Comparison of hormone levels in nipple aspirate fluid of pre- and postmenopausal women: Effect of oral contraceptives and hormone replacement, J Clin Endocrinol Metab 90:1686-1691, 2005
34. Nguyen M, Watanabe H, Budson AE, et al: Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 86:356-361, 1994
35. Liu Y, Wang JL, Chang H, et al: Breast-cancer diagnosis with nipple fluid bFGF. Lancet 356:567, 2000 (letter)
36. Hsiung R, Zhu W, Klein G, et al: High basic fibroblast growth factor levels in nipple aspirate fluid are correlated with breast cancer. Cancer J 8:303-310, 2002
37. Sauter ER, Chervoneva I, Diamandis A, et al: Prostate-specific antigen and insulin-like growth factor binding protein-3 in nipple aspirate fluid are associated with breast cancer. Cancer Detect Prev 26:149-157, 2002
38. Gold P, Freedman SO: Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med 121:439-462, 1965
39. Kuhajda FP, Offutt LE, Mendelsohn G: The distribution of carcinoembryonic antigen in breast carcinoma: Diagnostic and prognostic implications. Cancer 52:1257-1264, 1983
40. Diamandis EP, Yu H: Nonprostatic sources of prostate-specific antigen. Urol Clin North Am 24:275-282, 1997
41. Sauter ER, Tichansky DS, Chervoneva I, et al: Circulating testosterone and prostate-specific antigen in nipple aspirate fluid and tissue are associated with breast cancer. Environ Health Perspect 110:241-246, 2002
42. Sauter ER, Klein G, Wagner-Mann C, et al: Prostate-specific antigen expression in nipple aspirate fluid is associated with advanced breast cancer. Cancer Detect Prev 28:27-31, 2004
43. Stark A, Hulka BS, Joens S, et al: HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer. J Clin Oncol 18:267-274, 2000
44. Kuerer HM, Thompson PA, Krishnamurthy S, et al: High and differential expression of HER-2/neu extracellular domain in bilateral ductal fluids from women with unilateral invasive breast cancer. Clin Cancer Res 9:601-605, 2003
45. Duffy MJ, O'Grady P, Devaney D, et al: Urokinase-plasminogen activator, a marker for aggressive breast carcinomas: Preliminary report. Cancer 62:531-533, 1988
46. Foekens JA, Peters HA, Look MP, et al: The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res 60:636-643, 2000
47. Harbeck N, Kates RE, Look MP, et al: Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424). Cancer Res 62:4617-4622, 2002
48. Qin W, Zhu W, Wagner-Mann C, et al: Association of uPA, PAT-1, and uPAR in nipple aspirate fluid (NAF) with breast cancer. Cancer J 9:293-301, 2003
49. Furger KA, Menon RK, Tuckl AB, et al: The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med 1:621-632, 2001
50. Alexander H, Stegner AL, Wagner-Mann C, et al: Proteomic analysis to identify breast cancer biomarkers in nipple aspirate fluid. Clin Cancer Res 10:7500-7510, 2004
51. Hutchens TW, Nelson RW, Li CM, et al: Synthetic metal-binding protein surface domains for metal ion-dependent interaction chromatography: I. Analysis of bound metal ions by matrix-assisted UV laser desorption time-of-flight mass spectrometry. J Chromatogr 604:125-132, 1992
52. Petricoin EE, Paweletz CP, Liotta LA: Clinical applications of proteomics: Proteomic pattern diagnostics. J Mammary Gland Biol Neoplasia 7:433-440, 2002
53. Wulfkuhle JD, Liotta LA, Petricoin EF: Proteomic applications for the early detection of cancer. Nat Rev Cancer 3:267-275, 2003
54. Sauter ER, Zhu W, Fan XJ, et al: Proteomic analysis of nipple aspirate fluid to detect biologic markers of breast cancer. Br J Cancer 86:1440-1443, 2002
55. Tong W, Xie Q, Hong H, et al: Using decision forest to classify prostate cancer samples on the basis of SELDI-TOF MS data: Assessing chance correlation and prediction confidence. Environ Health Perspect 112:1622-1627, 2004
56. Petricoin EF, Ardekani AM, Hitt BA, et al: Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359:572-577, 2002
57. Villanueva J, Tempst P: OvaCheck: Let's not dismiss the concept. Nature 430:611, 2004 (letter)
58. Diamandis EP: OvaCheck: Doubts voiced soon after publication. Nature 430:611, 2004 (letter)
59. Li J, Zhang Z, Rosenzweig J, et al: Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 48:1296-1304, 2002